{
    "organizations": [],
    "uuid": "546ebc54ce670032c10a1cf53f68b6865f4c331a",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-glaxosmithkline-says-viiv-healthca/brief-glaxosmithkline-says-viiv-healthcare-launches-new-two-drug-hiv-study-idUSFWN1PY0ND",
    "ord_in_thread": 0,
    "title": "BRIEF-GlaxoSmithKline Says ‍ViiV Healthcare Launches New Two-Drug HIV Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - Glaxosmithkline Plc:\n* ‍VIIV HEALTHCARE LAUNCHES EIGHTH PHASE III STUDY IN TWO-DRUG REGIMEN PROGRAMME FOR HIV-1 TREATMENT​\n* ‍TANGO WILL SEEK TO ENROL APPROXIMATELY 550 ADULTS WITH HIV-1, FROM CLINICAL TRIAL SITES IN NORTH AMERICA, EUROPE, AUSTRALIA, AND JAPAN​\n* EXPECTS ‍RESULTS OF TANGO IN 2019 * STUDY TO INVESTIGATE DOLUTEGRAVIR AND LAMIVUDINE IN PATIENTS WITH HIV WHO HAVE ACHIEVED VIRAL SUPPRESSION ON TENOFOVIR ALAFENAMIDE FUMARATE-BASED REGIMEN​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-08T17:36:00.000+02:00",
    "crawled": "2018-02-09T17:00:44.007+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "glaxosmithkline",
        "plc",
        "healthcare",
        "launch",
        "eighth",
        "phase",
        "iii",
        "study",
        "regimen",
        "programme",
        "seek",
        "enrol",
        "approximately",
        "adult",
        "clinical",
        "trial",
        "site",
        "north",
        "america",
        "europe",
        "australia",
        "expects",
        "tango",
        "study",
        "investigate",
        "dolutegravir",
        "lamivudine",
        "patient",
        "hiv",
        "achieved",
        "viral",
        "suppression",
        "tenofovir",
        "alafenamide",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}